The Olivia Hodson Cancer Fund’s objective is to provide, “Support for research and clinical advancements within the departments of Oncology, Haematology and Bone Marrow Transplant at Great Ormond Street Hospital”.
Understanding more about relapse in young patients with acute lymphoblastic leukaemia
Funds donated by OHCF will enable haematologists at GOSH use a form of DNA sequencing to help them treat and prevent relapse of a common childhood cancer.
Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children. Although treatment for it has improved and the rate of survival has progressively increased, it is an aggressive disease and many patients still relapse. The outcome from relapse is poor, therefore it is essential that we understand more about the changes that occur at this stage.
In this study, researchers will use high throughput DNA sequencing (HTS) to identify all of the genetic mutations that occur in leukaemic cells during a relapse. As a result, they hope to be able to provide important information on the prevention and treatment of relapse in childhood ALL.
OHCF funds will constitute a ‘pump priming’ grant for this project, paying for the consumables required to deliver a small-scale proof of principle over a 12-month period. The GOSH team plan to publish the results of their new research in medical journals or present them internationally, before applying for further grants to conduct wider studies with a larger patient group.